The complement system - Structure, activation, regulation and functions;Komplementsystemet - Oppbygning, aktivering, regulering og funksjon

Tidsskrift for den Norske Laegeforening

Volumn 119, Issue 2, 1999, Pages 226-233

  Bjørge, Line ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT;

COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; HUMAN; IMMUNOLOGY; INFLAMMATION; INJURY; METABOLISM; PHYSIOLOGY; REVIEW;

COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; HUMANS; INFLAMMATION; WOUNDS AND INJURIES;

EID: 0033585271     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Bordet J. Sur le mode d'action des sérums préventifs. Ann Inst Pasteur (Paris) 1896; 10: 193-219.
2. Laurell AB. Jules Bordet - a giant in immunology. Scand J Immunol 1990; 32: 429-32.
3. Mollnes TE. Komplementsystemet - en fascinerende biologisk kaskade. Del 1 - fysiologiske aspekter. Tidsskr Nor Lægeforen 1989; 109: 2782-8.
4. Mollnes TE. Komplementsystemet - en fascinerende biologisk kaskade. Del 2 - kliniske aspekter. Tidsskr Nor Lægeforen 1989; 109: 2891-6.
5. Müller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem 1988; 57: 321-47.
6. Holmskov U, Malhotra R, Sim RB, Jensenius JC. Collectins: collagenous C-type lectins of the innate immune defense system. Immunol Today 1994; 15: 67-74.
7. Reid KB, Colomb MG, Loos M. Complement component Cl and the collectins: paralellels between routes of acquired and innate immunity. Immunology Today 1998; 19: 56-9.
8. Turner MW. The lectin pathway of complement activation. Res Immunol 1996; 147: 110-5.
9. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997; 386: 506-10.
10. Podack ER, Müller-Eberhard HJ. Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem 1979; 254: 9808-14.
11. Jenne DE, Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci USA 1989; 86: 7123-7.
12. Pinckard RN, Olson MS, Kelley RE, DeHeer DH, Palmer JD, O'Rourke RA et al. Antibody-independent activation of human Cl after interaction with heart subcellular membranes. J Immunol 1973; 110: 1376-82.
13. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974; 112: 2135-47.
14. Cooper NR, Jensen FC, Welsh RM jr., Oldstone MB. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 1976; 144: 970-84.
15. Clas F, Schmidt G, Loos M. The role of the classical pathway for the bactericidal effect of normal sera against gram-negative bacteria. Curr Top Microbiol Immunol 1985; 121: 19-72.
16. Pangburn MK, Müller-Eberhard HJ. The alternative pathway of complement. Springer Semin Immunopathol 1984; 7: 163-92.
17. Men S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci USA 1990; 87: 3982-6.
18. Meri S, Pangburn MK. Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun 1994; 198: 52-9.
19. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994; 15: 369-96.
20. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989; 264: 1-14.
21. Ziccardi RJ. A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. J Immunol 1982; 128: 2505-8.
22. Davis AE. Structure and function of Cl inhibitor. Behring Inst Mitt 1989; 84: 142-50.
23. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983; 80: 5066-70.
24. Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 1979; 76: 5867-71.
25. Scharfstein J, Ferreira A, Gigli I, Nussenzweig V. Human C4-binding protein. I. Isolation and characterization. J Exp Med 1978; 148: 207-22.
26. Whaley K, Ruddy S. Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science 1976; 193: 1011-3.
27. Seya T, Turner JR, Atkinson JP. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 1986; 163: 837-55.
28. Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein betalH for cleavage of C3b and C4b in solution. J Exp Med 1977; 146: 257-70.
29. Huey R, Bloor CM, Kawahara MS, Hugli TE. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am J Pathol 1983; 112: 48-60.
30. Sugita Y, Nakano Y, Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem 1988; 104: 633-7.
31. Schönermark S, Rauterberg EW, Shin ML, Loke S, Roelcke D, Hansch GM. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 1986; 136: 1772-6.
32. Zalman LS, Wood LM, Müller-Eberhard HJ. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA 1986; 83: 6975-9.
33. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990; 71: 1-9.
34. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144: 3478-83.
35. Ross GD, Medof ME. Membrane complement receptors specific for bound fragments of C3. Adv Immunol 1985; 37: 217-67.
36. Hugli TE. Structure and function of the anaphylatoxins. Springer Semin Immunopathol 1984; 7: 193-219.
37. Kinoshita T. Complement receptors and regulation of humoral immune response. I: Cruse JM, Lewis RJ jr., red. Complement today. Basel: Karger, 1993: 46-55.
38. Pascual M, Schifferli JA. Another function of erythrocytes: transport of circulating immune complexes. Infusionsther Transfusionsmed 1995; 22: 310-5.
39. Barbosa JE, Harrison RA, Barker PJ, Lachmann PJ. An anti-peptide antibody that recognizes a neo-antigen in the CR1 stump remaining on erythrocytes after proteolysis. Clin Exp Immunol 1992; 87: 144-9.
40. Morgan BP. Physiology and pathophysiology of complement: progress and trends. Crit Rev Clin Lab Sci 1995; 32: 265-98.
41. Würzner R, Dierich MP. Complement in human disease. Immunol Today 1997; 18: 460-3.
42. Mollnes TE. Biocompatibility: complement as mediator of tissue damage and as indicator of incompatibility. Exp Clin Immunogenet 1997; 14: 24-9.
43. Weisman HF, Bartow T, Leppo MK, Marsh HC jr., Carson GR, Concino MF et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146-51.
44. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995; 268: H448-57.
45. Rollins SA, Matis LA, Springhorn JP, Setter E, Wolff DW. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation 1995; 60: 1284-92.
46. Riethmüller G, Schneider-Gadicke E, Johnson JP. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993; 5: 732-9.
47. Bjørge L, Hakulinen J, Wahlström T, Matre R, Meri S. Complement-regulatory proteins in ovarian malignancies. Int J Cancer 1997; 70: 14-25.